Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
They are not doing the same thing
The impact of Wegovy on the Medicare population may not be as significant as the impact commercial payers have seen when choosing to cover Wegovy, given the concomitant prevalence of diabetes and overweight/obesity in Americans over age 65
Further, the results may suggest superiority to other treatment classes, specifically SGLT-2 inhibitors, DPP-4 inhibitors, TZD, and SUs
Lilly notes that approximately half of the people on employer-sponsored plans dont receive coverage for obesity
US$ 25.06
US$ 20.15
US$ 24.11
US$ 27.14
US$ 29.93
